Interactions between *Mycoplasma mycoides* subsp. *mycoides* and bovine macrophages under
physiological conditions

Philippe Totté*[1], Tiffany Bonnefois[1], Lucia Manso-Silván [1]

[1] ASTRE, CIRAD, INRAE, Univ Montpellier – Montpellier, France

*Corresponding author
Correspondence: philippe.totte@cirad.fr

ABSTRACT
We investigated the interactions of unopsonized and opsonized *Mycoplasma mycoides* subsp.
mycoides (*Mmm*) with bovine macrophages *in vitro*. *Mmm* survived and proliferated extracellularly on
bovine macrophage cell layers in the absence of *Mmm*-specific antisera. Bovine complement used at
non-bactericidal concentrations did neither have opsonizing effect nor promoted intracellular
survival, whereas *Mmm*-specific antisera substantially increased phagocytosis and *Mmm* killing. A
phagocytosis-independent uptake of *Mmm* by macrophages occurred at a high multiplicity of
infection, also found to induce the production of TNF, and both responses were unaffected by non-
bactericidal doses of bovine complement. Bovine complement used at higher doses killed *Mmm* in
cell-free cultures and completely abrogated TNF responses by macrophages. These results provide a
framework to identify *Mmm* antigens involved in interactions with macrophages and targeted by
potentially protective antibodies and point towards a pivotal role of complement in the control of
inflammatory responses in contagious bovine pleuropneumonia.

Keywords: Contagious bovine pleuropneumonia, *Mycoplasma mycoides*, macrophages, complement,
TNF

Introduction

Mycoplasma mycoides subsp. *mycoides* (*Mmm*) is a wall-less bacterium and the causative
agent of contagious bovine pleuropneumonia (CBPP), a highly contagious respiratory disease of cattle
notifiable to the World Organization for Animal Health [1]. CBPP lung lesions and chronic carrier state
are suggestive of an uncontrolled inflammatory response by the host's immune system and immune
evasion mechanisms developed by *Mmm* respectively [2]. Although macrophages patrolling the
surface of respiratory mucosae represent the first line of defense against pathogens invading the lung,
little is known of the interactions of these cells with *Mmm*. Macrophages containing *Mmm* antigens
are found in the lungs of infected animals [3] and they produce the archetypal pro-inflammatory
cytokine TNF upon infection *in vitro* [4]. However, studies investigating the fate of *Mmm* in the
presence of macrophages are lacking.
Another major contributor to the host defense against infection is the complement system.
Complement proteins are present in extracellular fluids allowing direct killing and non-specific
opsonization, followed by increased phagocytosis of pathogens [5]. Non-specific opsonization can
result in killing but also in intracellular survival if pathogens are able to prevent fusion of phagosomes
with lysosomes [6, 7]. Upon activation, the complement promotes inflammation through the
induction of pro-inflammatory cytokines [8, 9]. These pleiotropic effects of complement are not
exclusive and may be dose-dependent. For example, the complement membrane attack complex

responsible for the pathogen killing activity of complement can also induce the production of pro-
inflammatory cytokines by phagocytes when used at non-bactericidal doses [9]. Thus, in CBPP,
interactions between *Mmm*, macrophages and complement may either benefit the host, through
direct or opsonization-mediated killing of *Mmm* or: paradoxically; harm the host, through
opsonization-mediated intracellular survival of *Mmm* and amplification of inflammatory responses.
Although previous work suggests that mycoplasmas are generally phagocytosed by
macrophages only in the presence of specific antiserum [10], the question remains open for *Mmm*.
Also, effects of complement other than opsonization, such as direct killing and cytokine production,
may impact disease outcome in CBPP. Therefore, the following study was undertaken to investigate
the interaction of bovine macrophages with *Mmm* under physiological conditions, *i.e.*, in the presence
of complement prepared from the same cell donor. Firstly, the effect of bovine complement on the
viability of *Mmm* was analyzed to determine non-bactericidal concentrations. Secondly, the uptake of
Mmm by macrophages and subsequent extra- and intracellular survival in the presence of bovine
complement at non-bactericidal doses was investigated. Finally, we addressed the possibility that
complement acts as a potentiator of *Mmm*-induced TNF responses of macrophages.
62
63
64   **Methods**
65
Bacterial strains
Non-fluorescent *Mmm* strain 8740-Rita and *Mycoplasma bovis* strain Oger2, and fluorescent
mNeonGreen-expressing *Mmm* mutant strain 8740-Rita clone 6 (RN6), were grown in PPLO-based
medium as described previously [11]. Mycoplasmas obtained from log-phase cultures were washed
once in PBS by centrifugation at 10000 x *g* for 10 min before resuspension in macrophage culture
medium (see below) at 1-$2x10^9$ colony forming units per mL, or CFU/ml, as determined through
dilution and plating on PPLO-based media supplemented with 1 % Noble Agar (Difco, USA). Briefly,
serial 10-fold dilutions in PBS were prepared in a final volume of 500μL with a change of tip and
vortexing between each tube. 20μL from each tube were spotted onto PPLO agar plates and incubated
at 37°C for four days before counting the colonies under a light microscope.
76
77
Bovine complement and antiserum
Non-decomplemented bovine sera obtained from 3 adult Jersey cattle housed at Cirad's animal
facility served as a source of complement. These animals were purchased in France were CBPP has
been eradicated and were kept outdoor after approval by the Languedoc-Roussillon regional ethics
committee (French CE-LR#36) in the authorized project using animals for scientific
purposesAPAFIS#27628. Sera were aseptically collected from whole blood tubes after clotting for 30
min at room temperature at 19-23°C, followed by centrifugation at 800 x g for 20 min. Single-use
aliquots of non-decomplemented sera were kept in liquid nitrogen until use after quick thawing at 37°C.
Bactericidal capacities of bovine complement were assessed by incubation of $1x10^6$-$1x10^8$ viable *Mmm*
with different concentrations of non-decomplemented bovine sera at 100 μL/well in 96-well flat-
bottom-plates for 1 h at 37°C and 5% CO_2 before vortexing and CFU titration. That range of viable
Mmm corresponds to the lowest and highest number of bacteria used to infect macrophages. The specific
Mmm antiserum was obtained by pooling sera from two-years old Zebu cattle recovering from an
experimental infection with *Mmm* strain 8740-Rita [12]. These animals were selected on the basis of
their positivity using a CBPP-specific cELISA [13] and a record of clinical signs typical of CBPP. Prior
to use, *Mmm* antisera were decomplemented by heating at 56°C for 30min.
94
Macrophages and bacterial infection
Macrophages were derived from monocytes obtained from the same three animals used to
prepare non-decomplemented bovine sera. Briefly, monocytes were purified from PBMC by positive
selection of CD14+ cells using anti-human CD14 magnetic beads (Miltenyi, Germany) according to the
manufacturer's instructions. Monocytes were resuspended in Iscove's Modified Dulbecco's Medium

(IMDM) supplemented with 2 mM L-glutamine, 50 μM 2-mercaptoethanol, 0.4 mg/mL ampicillin and
10% heat-inactivated fetal calf serum (FCS; Eurobio AbCys, France), seeded at 3 x 10^5cells/well of 96-
well flat-bottom-plates in 200 μl, and incubated for 6 days at 37°C and 5% CO_2 with a change of half
of the medium at day 3. Before infection, the medium was removed and replaced with IMDM lacking
FCS to which the following stimuli were added to reach a final volume of 100 μl/well: i) appropriate
amounts of mycoplasmas to obtain MOIs of 1, 10 and 100; and ii) non-decomplemented autologous
bovine sera or antiserum or FCS. Non-decomplemented bovine sera were used at non-bactericidal doses
ranging from 5 to 10% v/v depending on the donor, whereas antiserum was used at 20% v/v and FCS
at 10% v/v. After 1 h incubation, the medium was replaced and 100μl of complete IMDM medium was
added to the wells before harvesting or further incubation. For harvesting macrophages, monolayers
were scrapped off using 200μl tips, pelleted by centrifugation at 500 x g for 5 min, resuspended in 200
μL PBS, and passaged 5 times through a 27gauge needle, which lysed more than 80% of cells as shown
by Trypan blue viability counts. *Mmm* CFU titers were determined as described above. For gentamycin
assays, an MOI of 10 was used, as it was shown in preliminary macrophage-free assays that addition of
400 μg/ml of gentamicin to the culture for 3 hours reliably killed 100% of mycoplasmas. Cultures
infected with *M. bovis* strain Oger2 were used as positive controls of intracellular survival in the
presence of gentamycin [14].
117
Flow cytometry
Macrophages were infected with fluorescent and non-fluorescent *Mmm* at MOIs of 500-1000
as described above. Due to the high MOI, non-decomplemented bovine sera could be used at up to 40%
v/v without affecting *Mmm* viability. Before harvesting, the medium was replaced by 100 μl/well of
fresh medium and cells were scraped off, homogenized by pipetting up and down, and transferred to 5
ml cytometry tubes. After addition of 10 μL/tube of propidium iodide (PI, BD Biosciences, USA) and
10min incubation at 4°C in the dark, 100 μL of sheath fluid was added to each tube. Preliminary
macrophage-free tests showed that 100% of *Mmm* took up PI in these conditions. Since PI and
mNeonGreen fluoresce in different wavelength, it was possible to gate out PI positive macrophages to
exclude dead cells (i.e., with loss of membrane integrity) and extracellular *Mmm*. This allowed analysis
of strictly intracellular mNeonGreen-dependent fluorescence. CytochalasinD (Sigma, France), an
inhibitor of actin-dependent phagocytosis, was used at 10 μg/ml. At least 5000 events were analyzed
within the PI negative gate with a FacsCanto flow cytometer (BD Biosciences) equipped with the
FacsDiva software (BD Biosciences). Gates and quadrants were used to delineate populations of interest
and calculate statistics respectively. Results were expressed in percentages of cells fluorescing above
background (*i.e*., fluorescence produced by macrophages infected with non-fluorescent *Mmm*) and
geometric mean fluorescence intensity (MFI), which is proportionally related to numbers of
mNeonGreen+ *Mmm* per cell.
136
ELISA
Supernatants were collected from macrophage cultures infected as above for 24 h with *Mmm* at
MOIs ranging from 100 to 1000 and stored at -20°C until use. Non-decomplemented bovine sera were
used at both bactericidal and non-bactericidal concentrations and the highest dose was also used for
FCS. Lipopolysaccharide (LPS) from *Escherichia coli* 0111:B4 (Invivogen, France), used at 2 μg/ml,
served as a positive control. To quantify bovine TNF, a sandwich ELISA was performed using a
matched antibody pair (BioRad, France) as previously described [15]. Supernatants were tested in
duplicates and results obtained from a labsystems multiskan MS ELISA reader were expressed in mean
optical densities.
146
147 **Statistics**
148 A non-parametric Mann–Whitney U-test (https://www.socscistatistics.com/tests/mannwhitney/)
149 was used to analyze differences between responses obtained with various stimuli. Single and double
150 asterisks represent *p* values of <0.05 and <0.01 respectively. A difference was considered to be
151 significant at a *p* value of <0.05.
152
153 **Results**

154
Bactericidal effect of bovine complement on *Mmm* viability in the absence of macrophages
A dose-dependent effect of non-decomplemented bovine sera, containing bovine complement,
on *Mmm* CFU titers was observed *in vitro* (Fig1a). Depending on the dose and animals used the decrease
in CFU titers varied between 0 and 3 logs, indicating a potent effect of bovine sera and a high variability
among animals. There was no sign of *Mmm* aggregation induced by non-decomplemented serum when
cultures were checked under a light microscope, and passage through a 27G needle had no impact on
CFU titers, indicating that reduced viability occurred through direct cytotoxicity. The killing effect was
due to complement since it was neutralized by heating sera at 56°C for 30 min (Fig1b) a method known
to inactivate complement [5]. The mycoplasmacidal activity and inter-animal variability of bovine sera
remained consistent throughout the study (Supplementary Fig1).
165

166
167
168   **Figure1:** Cytotoxic effect of bovine complement on *Mmm* in vitro before a) and after b)
169 heating at 56°C. *Mmm* was incubated for 1 h with decomplemented sera (FCS) or different
170 concentrations (10%, 20%) of bovine sera from 3 different animals (s+animal number). Results from
171 3 different experiments are shown as mean+/-SD of CFU expressed in log10. Asterisks and bars
172 indicate statistically significant differences with FCS.
173
Effect of bovine complement on *Mmm* opsonization and survival in the presence of macrophages
A protocol was used to focus on *Mmm* associated to macrophages and to exclude non-adherent
and plastic-adherent mycoplasmas from the analysis (see methods). Furthermore, no cytopathological
effects of *Mmm* on macrophage monolayers were detected at any MOI used. In the absence of bovine
complement and antiserum, complete survival of *Mmm* occurred at 24 h and growth of up to 1 log was
observed at 48h, indicating no killing activity by macrophages (Fig2). Similar trends were observed at
MOIs of 1 and 100 whereas only survival of *Mmm* without growth (i.e., CFU titers remained constant)
was observed in the absence of macrophages (Supplementary Fig.2). The addition of non-
decomplemented bovine sera at non-bactericidal concentrations had no effect on *Mmm* viability at any
time-points (Fig2). As expected, addition of *Mmm*-specific antiserum induced significant killing
activity after 24 h and up to 2.5 logs decrease in CFU titers at 48h (Fig2).
185

186
Figure 2: Macrophages do not kill *Mmm* even in the presence of bovine complement.
Macrophages were infected with *Mmm* at an MOI of 10 in the absence (FCS) or presence (serum) of
non-decomplemented bovine sera at non-bactericidal concentrations and incubated for 1, 24, and 48h
before assessment of macrophages-associated *Mmm* titers. Anti-*Mmm* antiserum (antiserum) was
added to additional wells as positive controls of bactericidal activity. Results from 3 different
experiments using 3 animals are shown as mean+/-SD of CFU expressed in log10. Asterisks indicate
statistically significant differences with FCS.
194
In order to analyze intracellular survival of *Mmm* experiments were repeated in the presence of
gentamicin to kill all extracellular mycoplasmas. This was performed only at an MOI of 10, which
represented a concentration of 3×10^6 CFU/ml of *Mmm*, since gentamicin did not kill 100% extracellular
mycoplasmas at higher *Mmm* concentrations. As seen in Fig.3, gentamicin assays indicated that the
overwhelming majority of *Mmm* survival at 24 h was due to extracellular mycoplasmas and that bovine
complement had no effect on *Mmm* survival inside macrophages. This was not due to a bias in
gentamicin assay since significant survival was observed with *M. bovis* Oger2 (Fig3).
202
203

204
205
Figure 3: Bovine complement has no impact on *Mmm* survival inside macrophages.
Macrophages were infected with *Mmm* at an MOI of 10 in the absence (FCS) or presence (serum) of
bovine complement at non-bactericidal concentrations and incubated for 24 h. Cells were then treated
for 4-hours with gentamycin before harvesting and assessment of macrophage-associated *Mmm* titers.
Wells containing macrophages infected with *M. bovis* (Oger2) were used as positive controls of
intracellular survival in the presence of gentamycin. Results from 3 different experiments using 3
animals are shown as mean+/-SD of CFU expressed in log10.
213
Effect of bovine complement on the uptake of fluorescent *Mmm* by macrophages

We were able to analyze *Mmm*-dependent intracellular fluorescence by gating out extracellular
fluorescence as explained in "Methods". As seen in Fig4, in the absence of bovine complement or
antiserum, more than 90% of macrophages had engulfed fluorescent *Mmm* but at low levels as indicated
by low FITC fluorescence intensity ("Li" in Fig4a). Indeed, FITC signals did not exceed one log above
background level and could not be detected when MOIs of 100 or less were used (data not shown). No
differences were detected between 1 and 24 h PI in both percentages of positive cells and MFI (Fig4a
and Fig4b). Non-decomplemented bovine sera used at non-bactericidal concentrations had no effect on
FITC fluorescent levels at any time-points (Fig4a and Fig4b). Data at 48h were not exploitable due to
high background fluorescence. The low-level uptake was not affected by cytochalasinD ("Li" in Fig4c)
indicating that it was not dependent on phagocytosis. A substantially stronger FITC fluorescence
intensity was observed in the presence of antiserum indicating a strong increase in *Mmm* uptake by
macrophages ("Hi" in Fig4a). At 24 h PI, the % of cells within the "Hi" gate increased while the mean
fluorescence intensity decreased (gate P5 and MFI in Fig4b) suggesting partial destruction of
fluorescent *Mmm* within macrophages. Moreover, the vast majority of highly fluorescent cells
disappeared in the presence of cytochalasinD (FIg4c) indicating that the uptake of *Mmm* by
macrophages in the presence of antiserum was dependent on phagocytosis.
The lack of effect by bovine complement on the uptake of *Mmm* by macrophages was
confirmed for all three animals tested (Table1). Indeed, the addition of non-decomplemented bovine
sera at non-bactericidal concentrations had no impact on numbers of positive cells and MFI when
compared to FCS at 1 h and 24 h PI. In addition, the positive effect of antiserum on *Mmm* uptake was
confirmed as well as the increase in percentage of positive cells at 24 h PI accompanied by a decrease
in MFI, indicating progressive destruction of phagocytized fluorescent *Mmm*.
237

238
Figure 4: Bovine complement does not impact *Mmm* uptake by macrophages. Macrophages were
infected with either non-fluorescent or fluorescent *Mmm* at an MOI of 500-1000, and either in the
absence (FCS) or in the presence (serum) of non-decomplemented bovine sera at non-bactericidal
concentrations. They were incubated for 1 h (a) and 24 h (b) before analysis of intracellular FITC
fluorescence by flow cytometry (see Methods). Finally, the effect of cytochalasinD, an inhibitor of
phagocytosis, on *Mmm* uptake by macrophages is shown in c). Anti-*Mmm* antiserum (antiserum) was
added to additional wells as positive control of specific phagocytosis. Typical histogram plots are
shown for one representative animal as an example. Histograms and arrows display background (bgd,
hatched line), and low (Li, green line) and high (Hi, green line) fluorescence intensities produced by
macrophages infected with non-fluorescent and fluorescent *Mmm* respectively. Percentages of highly
249   fluorescent cells and MFI are given by the P5 interval.

250 **Table 1:** Effect of bovine complement (serum) from three different animals (mean+/-SD) on the uptake of fluorescent *Mmm* by
251 autologous macrophages as measured by flow cytometry 1 h and 24 h post infection

Stimuli	Low fluorescence intensity[a]				High fluorescence intensity[a]			
	% pos [b]		MFI[c]		% pos [b]		MFI[c]	
	1 h	24 h	1 h	24 h	1 h	24 h	1 h	24 h
FCS	93+/-2	96+/-5	1013+/-33	995+/-33	7+/-3	10+/-1	NA	NA
Serum	92+/-3	99+/-3	1008+/-52	1050+/-42	8+/-4	9+/-2	NA	NA
Antiserum[d]	NA	NA	NA	NA	63+/-10	94+/-5	14518 +/-1313	6905 +/-948

(a): low and high fluorescence intensities above background fluorescence (see also Figure 4)
(b): Percentages of positive cells
(c): Mean fluorescence intensity
(d): sera from CBPP convalescent animals
NA: not applicable. The effect of antiserum is measurable only within the high fluorescence intensity whereas, in the presence of
complement, the vast majority of positive cells were found in the low fluorescence intensity range.
269

Effect of bovine complement on *Mmm*-induced TNF production by macrophages

As shown in Fig5, in the absence of bovine sera and antiserum, *Mmm* induced the production of TNF by macrophages when MOIs of 500-1000 were used. At an MOI of 100, TNF was not detected (not shown). There was no effect of bovine complement at non-bactericidal doses (Fig.5, serum1). In order to analyze the effect of non-decomplemented bovine sera at bactericidal doses, concentrations of both non-decomplemented bovine sera and FCS had to be increased. For one animal, a substantial increase in background (*i.e.,* TNF induced by FCS alone in the absence of *Mmm*) prevented its use. Nevertheless, non-decomplemented bovine sera from the remaining two animals, used at bactericidal concentrations inducing at least 1log decrease in *Mmm* viability, almost completely abrogated the production of TNF induced by *Mmm* (Fig5, serum2).

Figure 5 : Effect of bovine complement on *Mmm*-induced release of TNF by autologous macrophages. Macrophages were either left uninfected (*Mmm-*) or infected (*Mmm+*) with *Mmm* at an MOI of 500-1000 in either the absence (FCS) or presence of non-decomplemented bovine sera at non-bactericidal (serum1) and bactericidal (serum2) concentrations and incubated for 24 h before TNF titration of supernatants. Lipopolysaccharide (LPS) was added to additional wells as positive controls. Results from 3 different experiments using complement from two animals are shown as mean+/-SD of optical densities (OD). Asterisks indicate statistically significant differences.

Discussion

Given their pivotal role in first-line immune defenses against mucosal pathogens, we have
investigated the interactions between macrophages and *Mmm*, the causal agent of CBPP. Non-
decomplemented bovine sera were used as a source of complement to mimic physiological conditions
present at infected sites and cryopreservation in liquid nitrogen was instrumental in overcoming the
instability of complement. The strong bactericidal effect of some non-decomplemented bovine sera on
Mmm viability that we observed in this study is in conflict with previous work [16]. One likely
explanation is that we used bovine sera instead of guinea pig sera. Similarly, non-decomplemented
caprine sera was found to reduce the viability of *Mycoplasma mycoides* subsp. *capri* (*Mmc*), *Mmm*'s
closest relative [17]. Given its stability over time *in vivo* and variable potency between animals, it would
be interesting to assess whether a correlation exists between the anti-*Mmm* effect of bovine sera and the
resistance of animals to CBPP. Considering the pleiotropic effects of complement on immune responses
to pathogens, we have explored the possible impact of bovine complement, used at non-bactericidal
concentrations, on important functions of macrophages such as non-specific opsonization-mediated
phagocytosis and production of pro-inflammatory TNF.
In the first place, we analyzed the kinetics of *Mmm* survival in the presence of bovine
macrophages and in the absence of complement and antiserum. Lysis of macrophages prior to *Mmm*
titration allowed taking into account both intracellular and membrane-associated mycoplasmas. *Mmm*
CFU titers remained stable after 24 h and increased by up to 1log after 48h, indicating the absence of
measurable killing by macrophages. Little or negligible numbers of macrophage-associated *Mmm*
survived intracellularly in the presence of gentamicin, suggesting that viable *Mmm* were mainly located
on cell membranes. Absence of killing by macrophages or even growth on macrophages in the absence
of specific antiserum and complement has been reported previously for other mycoplasmas [10, 18].
We found no measurable effect of bovine complement on *Mmm* CFU titers, suggesting that neither non-
specific opsonization-mediated killing nor intracellular survival occurred under our experimental
conditions. It should be noted that pre-incubation of *Mmm* with bovine complement for 30 min at 37°C
before infecting macrophages rather than concomitantly did not change the results. However, we cannot
exclude the possibility that the presence of *Mmm* growing on macrophages masks a low-level killing
activity. On the other hand, *Mmm* titers substantially decreased over time when anti-*Mmm* antiserum
was added to the medium indicating that intrinsic killing capacities of macrophages were not altered.
Again, absence of killing by macrophages, even in the presence of complement, has been shown
previously for several mycoplasmas [10]. It is possible that the presence of a polysaccharide capsule
[19] protects non-opsonized and non-specifically opsonized *Mmm* from phagocytosis [20] which may
be further investigated using non capsulated variants [16].
In order to gain a better insight on the interactions of *Mmm* with bovine macrophages, we used
a more direct approach based on flow cytometry-assisted monitoring of intracellular fluorescence of
phagocytes after infection with fluorescent *Mmm*. Our results show that, in the absence of complement
and antiserum, more than 90% of macrophages take up fluorescent *Mmm* at low levels, as indicated by
low mean fluorescence intensities. Unfortunately, in macrophages-free cultures, gentamicin was not
100% bactericidal at the *Mmm* concentrations used for flow cytometry.Thus, preventing assessment of
the viability of intracellular fluorescent *Mmm*. The lack of decrease in fluorescence over time suggests
that either no killing occurred or that it was not sufficient to cope with ongoing growth of *Mmm* on
macrophages. CytochalasinD had no effect on the number of cells harboring low intracellular
fluorescence, suggesting that the uptake of *Mmm* by macrophages was independent of phagocytosis.
Interestingly, it has recently been shown that *Mmc* interacts with C-type lectin receptors (CTLRs) [21]
some of which mediate endocytosis. Several CTLRs are present on macrophages, which warrants
further studies on their potential role in CBPP. Moreover, pathogen-associated molecular patterns
(PAMPs) of *Mmm* recognized by these receptors have potential as virulent factors. Bovine complement
used at non-bactericidal concentrations had no effect on the uptake of *Mmm* by macrophages at any
time points, confirming viability experiments using CFU titration. On the other hand, anti-*Mmm*
antiserum induced a strong and phagocytosis-dependent increase in *Mmm* uptake leading to more than
90% of cells located in the high fluorescence intensity gate at 24 hpi. Moreover, the mean fluorescence

intensity within that gate decreased at 24 hpi confirming the progressive destruction of *Mmm* as seen with CFU titration. These last results are intriguing since *Mmm* and related mycoplasmas possess a two-protein system capable of cleaving immunoglobulins G (IgG) [22]. Decomplementation of anti-*Mmm* antisera did not affect their opsonizing potency indicating that IgGs are most likely involved.

Our results confirm previous work demonstrating the capacity of *Mmm* to induce TNF production by alveolar macrophages in the absence of either complement or antiserum (Jungi et al., 1996). Our results show that the use of peripheral blood-derived MDMs represents a valid alternative to alveolar macrophages, whose preparation requires greater expertise and has a greater impact on animal welfare. Interestingly, TNF was induced only at high MOIs (i.e., >500) also shown by flow cytometry to be associated with phagocytosis-independent engulfment of *Mmm*. This suggests a possible involvement of autophagy in the pro-inflammatory response of macrophages to *Mmm*. There was no beneficial effect of bovine complement on the TNF response of infected macrophages when used at non-bactericidal concentrations. The effect of bovine complement at bactericidal doses was also analyzed, considering the possible release of pro-inflammatory molecules from *Mmm* undergoing lysis. We found that, when used at bactericidal concentrations, bovine complement efficiently abrogated the production of TNF by macrophages in response to *Mmm* infection.

In summary, using a combination of CFU titration, gentamicin assays, fluorescent *Mmm*, and TNF ELISA, we were able to show that: i) macrophages were not capable of killing *Mmm* efficiently in the absence of antiserum; ii) bovine complement used at non-bactericidal doses neither had opsonizing effect nor did it promote intracellular survival; iii) bovine complement did not impact the phagocytosis-independent *Mmm* uptake by macrophages that occurred in the absence of antiserum; iv) bovine complement used at non bactericidal concentrations did not amplify *Mmm*-induced TNF responses of macrophages, and even abrogated that response when used at concentrations inducing bactericidal activity. These results provide a framework to identify PAMPs as well as *Mmm* antigens recognized by CTLRs and protective antibodies. In addition, they point towards a role for complement in the control of TNF-dependent inflammatory responses in CBPP.

References

1. World Organization for animal Health (2015). https://www.woah.org/en/what-we-do/animal-health-and-welfare/animal-diseases/?_alphabet=C. Accessed 20 Sept 2022

2. Provost A, Perreau P, Bréard A. Contagious bovine pleuropneumonia (1987) Rev Sci Tech Off. int. Epiz., 6 (3), 625-679. https://doi.org/10.20506/rst.6.3.306

3. Scanziani E, Paltrinieri S, Boldini M, Grieco V, Monaci C, Giusti AM, Mandelli G (1997) Histological and immunohistochemical findings in thoracic lymph nodes of cattle with contagious bovine pleuropneumonia. J Comp Pathol. Aug;117(2):127-36.https://doi.org/10.1016/s0021-9975(97)80029-1

4. Jungi TW, Krampe M, Sileghem M, Griot C, Nicolet J (1996) Differential and strain-specific triggering of bovine alveolar macrophage effector functions by mycoplasmas. Microb Pathog. 2:487–498. https://doi.org/10.1006/mpat.1996.0078

5. Volanakis J.E. (1998) Overview of the complement system, in: Volanakis J.E., Frank M.M., (Eds.), The human complement system in health and disease, Marcel Dekker Inc., New York, 1998, pp. 9–32. https://doi.org/10.1201/9780367800772

6. Cosma CL, Sherman DR, Ramakrishnan L. (2003) The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol 57:641-76. https://doi.org/10.1146/annurev.micro.57.030502.091033

7. Horwitz, M. A. (1983) The Legionnaires' disease bacterium (Legionella pneumophila) inhibits phagosome-lysosome fusion in human monocytes. J. Exp. Med. 158:2108- 2126. https://doi.org/10.1084/jem.158.6.2108.

8. Okusawa S, Yancey KB, van der Meer JW, Endres S, Lonnemann G, Hefter K, Frank MM, Burke JF, Dinarello CA, Gelfand JA. (1988) C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med. 1;168(1):443-8. https://doi.org/10.1084/jem.168.1.443

9. Laudisi F, Spreafico R, Evrard M, Hughes TR, Mandriani B, Kandasamy M, Morgan BP, Sivasankar B,
Mortellaro A. (2013) Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation
and IL-1β release. J.Immunol. Aug 1;191(3):1006-10. https://doi.org/10.4049/jimmunol.1300489
10. Marshall AJ, Miles RJ, Richards L. (1995) The phagocytosis of mycoplasmas. J Med Microbiol.
Oct;43(4):239-50. https://doi.org/10.1099/00222615-43-4-239
11. Bonnefois T, Vernerey MS, Rodrigues V, Totté P, Puech C, Ripoll C, Thiaucourt F, Manso-Silván L. (2016)
Development of fluorescence expression tools to study host-mycoplasma interactions and validation in
two distant mycoplasma clades. J Biotechnol. Oct 20;236:35-44.
https://doi.org/10.1016/j.jbiotec.2016.08.006
12. Yaya A, Golsia R, Hamadou B, Amaro A, Thiaucourt F. Essai comparatif d'efficacité des deux souches
vaccinales T1/44 et T1sr contre la péripneumonie contagieuse bovin. Rev Elev Med Vet Pays Trop.
1999;52(3-4):171-179. https://www.vetres.org/articles/vetres/pdf/2006/05/v6049.pdf
13. Le Goff C., Thiaucourt F., 1998. A competitive ELISA for the specific diagnosis of contagious bovine
pleuropneumonia (CBPP). Vet. Microbiol., 60: 179-191.
https://www.sciencedirect.com/science/article/pii/S0378113598001564
14. Suleman M, Prysliak T, Clarke K, Burrage P, Windeyer C, Perez-Casal J. (2016) Mycoplasma bovis isolates
recovered from cattle and bison (Bison bison) show differential in vitro effects on PBMC proliferation,
alveolar macrophage apoptosis and invasion of epithelial and immune cells. Vet Microbiol. Apr
15;186:28-36. https://doi.org/10.1016/j.vetmic.2016.02.016
15. Totté P, Puech C, Rodrigues V, Bertin C, Manso-Silvan L, Thiaucourt F. (2015) Free exopolysaccharide
from Mycoplasma mycoides subsp. mycoides possesses anti-inflammatory properties. Vet Res. Oct
21;46:122. https://doi.org/10.1051/vetres:2007046
16. Gaurivaud P, Lakhdar L, Le Grand D, Poumarat F, Tardy F. (2014) Comparison of in vivo and in vitro
properties of capsulated and noncapsulated variants of Mycoplasma mycoides subsp. mycoides strain
Afadé: a potential new insight into the biology of contagious bovine pleuropneumonia. FEMS Microbiol
Lett. Oct;359(1):42-9. https://doi.org/10.1111/1574-6968
17. Schieck E, Lartigue C, Frey J, Vozza N, Hegermann J, Miller RA, Valguarnera E, Muriuki C, Meens J, Nene
V, Naessens J, Weber J, Lowary TL, Vashee S, Feldman MF, Jores J. (2016) Galactofuranose in
Mycoplasma mycoides is important for membrane integrity and conceals adhesins but does not
contribute to serum resistance. Mol Microbiol. Jan;99(1):55-70. https://doi.org/10.1111/mmi.13213.
18. Howard CJ, Taylor G, Collins J, Gourlay RN. (1976) Interaction of Mycoplasma dispar and Mycoplasma
agalactiae subsp. bovis with bovine alveolar macrophages and bovine lacteal polymorphonuclear
leukocytes. Infect Immun. Jul;14(1):11-7. https://doi.org/10.1128/iai.14.1.11-17.1976
19. Buttery, S.H. (1970) Hapten inhibition of the reaction between Mycoplasma mycoides polysaccharide
and bovine antisera. Immunochemistry, 7, 305-310. https://doi.org/10.1016/0019-2791(70)90168-0
20. Weis J.J., Law S.K., Levine R.P., Cleary P.P., (1985) Resistance to phagocytosis by group A streptococci:
Failure of deposited complement opsonins to interact with cellular receptors, J. Immunol. 134 (1985)
500–505.
21. Lindenwald DL, Monteiro JT, Rautenschlein S, Meens J, Jung K, Becker SC, Lepenies B. (2020) Ovine C-
type lectin receptor hFc-fusion protein library - A novel platform to screen for host-pathogen
interactions. Vet Immunol Immunopathol. Apr 18;224-230.
https://doi.org/10.1016/j.vetimm.2020.110047
22. Arfi Y, Minder L, Di Primo C, Le Roy A, Ebel C, Coquet L, Claverol S, Vashee S, Jores J, Blanchard A, Sirand-
Pugnet P. (2016) MIB-MIP is a mycoplasma system that captures and cleaves immunoglobulin G. Proc
Natl Acad Sci U S A. May 10;113(19):5406-11. https://doi.org/10.1073/pnas.1600546113
435
436

Code de champ modifié